SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

April 11, 2019 - The FDA approved Merck’s Keytruda (pembrolizumab), as a single agent, for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC), who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (Tumor Proportion Score [TPS] ≥ 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Download PDF